Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of cimetidine, a histamine type 2 receptor antagonist, on microcirculatory disturbance of the stomach induced by full-thickness burn injuries as a model for surgical stress in rats.

Current therapeutic research, clinical and experimental·2014

Same author

Postoperative long-term evaluation of interposition reconstruction compared with Roux-en-Y after total gastrectomy in gastric cancer: prospective randomized controlled trial.

American journal of surgery·2011

Same author

[Strategy for patients with GIST after failure of imatinib].

Gan to kagaku ryoho. Cancer & chemotherapy·2009

Same author

Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis.

Anticancer research·2009

Same author

Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines.

Oncology reports·2009

Same author

Subclassification of superficial cardia cancer in relation to the endoscopic esophagogastric junction.

Journal of gastroenterology and hepatology·2009

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

[Individualized tumor response assay].

Tetsuro Kubota¹

¹Center for Comprehensive and Advanced Medicine, Keio University Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|February 19, 2008

Summary

This summary is machine-generated.

An individualized tumor response (ITR) assay can identify patients likely to benefit from adjuvant chemotherapy after advanced gastric cancer surgery. This assay helps differentiate responders from non-responders, optimizing treatment selection for better survival outcomes.

More Related Videos

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

Related Experiment Videos

Last Updated: Jul 7, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

Area of Science:

Oncology
Cancer Research
Surgical Oncology

Context:

Advanced gastric cancer treatment often involves adjuvant chemotherapy post-surgery.
Identifying patient response to chemotherapy is crucial for treatment efficacy.
Current standard therapies show variable responses among gastric cancer patients.

Purpose:

To evaluate the utility of an individualized tumor response (ITR) assay in selecting appropriate adjuvant chemotherapy for gastric cancer.
To determine if the ITR assay can predict patient response to chemotherapy.
To improve survival outcomes for advanced gastric cancer patients through tailored chemotherapy.

Summary:

The study investigated the usefulness of an individualized tumor response (ITR) assay for advanced gastric cancer.
The ITR assay's accuracy was previously reported at 74% in Japan.
The assay aims to differentiate between patients who will respond and those who will not respond to adjuvant chemotherapy.

Impact:

The ITR assay can guide the selection of effective adjuvant chemotherapy, potentially improving survival rates.
It offers a method to personalize treatment strategies for gastric cancer patients.
This approach may lead to more efficient use of chemotherapy resources by avoiding ineffective treatments.